Trial Profile
Phase 4 Study of Response to EGFR-TKI and Correlation With C-met Expression and EGFR Gene Mutation in NSCLC Patients Treated With Erlotinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics; Pharmacogenomic
- Acronyms MENTOR
- 05 Apr 2017 Status changed from recruiting to completed, based on the results presented at the 108th Annual Meeting of the American Association for Cancer Research
- 05 Apr 2017 Results evaluating the prevalence and predictive role of c-MET and EGFR mutation in non-small cell lung cancer, presented at the 108th Annual Meeting of the American Association for Cancer Research.
- 03 Feb 2012 New trial record